title: Clinical pharmacokinetics of alpha 1-antitrypsin in homozygous PiZ deficient patients.
abstract: A pharmacokinetic study of alpha 1-antitrypsin (ATT) was performed in 2 groups of homozygous PiZ-deficient patients (treated and untreated) and 1 group of healthy volunteers. The distribution of the 131I-labelled protein corresponds to a 3-compartment model. The intravenously administered protein diffused quickly to the extravascular compartment where some retention occurred. No significant difference in AAT metabolism was observed between the 3 groups. The half-life of the injected protein is slightly longer than 2.5 days. The AAT protein was not stored. These results confirm the observations collected during the clinical trials. That is, a weekly infusion is necessary to obtain stable serum AAT concentrations. Monthly infusions are unable to maintain a 'plateau' phase. The periodicity may be limited to every 2 weeks.
authors.affiliation: Faculty of Medicine, Internal Medicine Department, Purpan Hospital, Toulouse, France.
authors.forename: J
authors.initials: J
authors.lastname: Constans
authors.forename: P
authors.initials: P
authors.lastname: Carles
authors.forename: A
authors.initials: A
authors.lastname: Boneu
authors.forename: J
authors.initials: J
authors.lastname: Arnaud
authors.forename: A E
authors.initials: AE
authors.lastname: Tufenkji
authors.forename: M C
authors.initials: MC
authors.lastname: Pujazon
authors.forename: C
authors.initials: C
authors.lastname: Tavera
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D005260:Female; D006207:Half-Life; D006720:Homozygote; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D010641:Phenotype; D000515:alpha 1-Antitrypsin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019896:alpha 1-Antitrypsin Deficiency
chemical_list: D000515:alpha 1-Antitrypsin